Department of Microbiology & Immunology

Student Publications

 

Cindy Buffone, Diaz-Griffero Lab

Fricke, T., C. Buffone, S. Opp, J. Valle-Casuso, and F. Diaz-Griffero. 2014. BI-2 destabilizes HIV-1 cores during infection and prevents binding of CPSF6 to the HIV-1 capsid. Retrovirology 11:120

Schulte, B., C. Buffone, S. Opp, F. Di Nunzio, D. A. De Souza Aranha Vieira, A. Brandariz-Nunez, and F. Diaz-Griffero. 2015. Restriction of HIV-1 requires the N-terminal region of MxB as a capsid-binding motif but not as a nuclear localization signal. J Virol 89:8599-8610

Buffone, C., B. Schulte, S. Opp, and F. Diaz-Griffero. 2015. Contribution of MxB oligomerization to HIV-1 capsid binding and restriction. J Virol 89:3285-3294

Thenin-Houssier, S., I. M. de Vera, L. Pedro-Rosa, A. Brady, A. Richard, B. Konnick, S. Opp, C. Buffone, J. Fuhrmann, S. Kota, B. Billack, M. Pietka-Ottlik, T. Tellinghuisen, H. Choe, T. Spicer, L. Scampavia, F. Diaz-Griffero, D. J. Kojetin, and S. T. Valente. 2016. Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. Antimicrob Agents Chemother 60: 2195-2208

Chen, N. Y., L. Zhou, P. J. Gane, S. Opp, N. J. Ball, G. Nicastro, M. Zufferey, C. Buffone, J. Luban, D. Selwood, F. Diaz-Griffero, I. Taylor, and A. Fassati. 2016. HIV-1 capsid is involved in post-nuclear entry steps. Retrovirology 13: 28

Bhattacharya, A., Z. Wang, T. White, C. Buffone, L. A. Nguyen, C. N. Shepard, B. Kim, B. Demeler, F. Diaz-Griffero, and D. N. Ivanov. 2016. Effects of T592 phosphomimetic mutations on tetramer stability and dNTPase activity of SAMHD1 can not explain the retroviral restriction defect. Sci Rep 6: 31353

 

 

 

 

Clare Burn, Herold Lab

Petro, C. D., B. Weinrick, N. Khajoueinejad, C. Burn, R. Sellers, W. R. Jacobs, Jr., and B. C. Herold. 2016. HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates. JCI Insight 1

 

 

 

Jordan Chinai, Zang Lab 

Zhao, R., J. M. Chinai, S. Buhl, L. Scandiuzzi, A. Ray, H. Jeon, K. C. Ohaegbulam, K. Ghosh, A. Zhao, M. D. Scharff, and X. Zang. 2013. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A 110:9879-9884

Jeon, H., V. Vigdorovich, S. C. Garrett-Thomson, M. Janakiram, U. A. Ramagopal, Y. M. Abadi, J. S. Lee, L. Scandiuzzi, K. C. Ohaegbulam, J. M. Chinai, R. Zhao, Y. Yao, Y. Mao, J. A. Sparano, S. C. Almo, and X. Zang. 2014. Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep 9:1089-1098

Janakiram, M., J. M. Chinai, S. Fineberg, A. Fiser, C. Montagna, R. Medavarapu, E. Castano, H. Jeon, K. C. Ohaegbulam, R. Zhao, A. Zhao, S. C. Almo, J. A. Sparano, and X. Zang. 2015. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin Cancer Res 21:2359-2366

Chinai, J. M., M. Janakiram, F. Chen, W. Chen, M. Kaplan, and X. Zang. 2015. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 36: 587-595

Janakiram, M., J. M. Chinai, A. Zhao, J. A. Sparano, and X. Zang. 2015. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology 4: e1026534

Koirala, P., M. E. Roth, J. Gill, J. M. Chinai, M. R. Ewart, S. Piperdi, D. S. Geller, B. H. Hoang, Y. V. Fatakhova, M. Ghorpade, X. Zang, and R. Gorlick. 2016. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep 6: 31154

Koirala, P., M. E. Roth, J. Gill, S. Piperdi, J. M. Chinai, D. S. Geller, B. H. Hoang, A. Park, M. A. Fremed, X. Zang, and R. Gorlick. 2016. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 6: 30093

Cheng, H., M. Janakiram, A. Borczuk, J. Lin, W. Qiu, H. Liu, J. M. Chinai, B. Halmos, R. Perez-Soler, and X. Zang. 2017. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res 23: 825-832

 

 

 

Evan Der, Putterman Lab 

Xia, Y., E. Eryilmaz, E. Der, R. D. Pawar, X. Guo, D. Cowburn, and C. Putterman. 2016. A peptide mimic blocks the cross-reaction of anti-DNA antibodies with glomerular antigens. Clin Exp Immunol 183: 369-379

Chalmers, S. A., J. Doerner, T. Bosanac, S. Khalil, D. Smith, C. Harcken, J. Dimock, E. Der, L. Herlitz, D. Webb, E. Seccareccia, D. Feng, J. S. Fine, M. Ramanujam, E. Klein, and C. Putterman. 2016. Therapeutic blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of Bruton's tyrosine kinase. Sci Rep 6: 26164

Der, E., S. Ranabothu, H. Suryawanshi, K. M. Akat, R. Clancy, P. Morozov, M. Kustagi, M. Czuppa, P. Izmirly, H. M. Belmont, T. Wang, N. Jordan, N. Bornkamp, J. Nwaukoni, J. Martinez, B. Goilav, J. P. Buyon, T. Tuschl, and C. Putterman. 2017. Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight 2

 

 

 

Max Fels, Chandran Lab 

Wec, A. Z., A. S. Herbert, C. D. Murin, E. K. Nyakatura, D. M. Abelson, J. M. Fels, S. He, R. M. James, M. A. de La Vega, W. Zhu, R. R. Bakken, E. Goodwin, H. L. Turner, R. K. Jangra, L. Zeitlin, X. Qiu, J. R. Lai, L. M. Walker, A. B. Ward, J. M. Dye, K. Chandran, and Z. A. Bornholdt. 2017. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169: 878-890

Zhao, X., K. A. Howell, S. He, J. M. Brannan, A. Z. Wec, E. Davidson, H. L. Turner, C. I. Chiang, L. Lei, J. M. Fels, H. Vu, S. Shulenin, A. N. Turonis, A. I. Kuehne, G. Liu, M. Ta, Y. Wang, C. Sundling, Y. Xiao, J. S. Spence, B. J. Doranz, F. W. Holtsberg, A. B. Ward, K. Chandran, J. M. Dye, X. Qiu, Y. Li, and M. J. Aman. 2017. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell 169: 891-904

 

 

 

Peter John, Zang Lab 

Sankin, A., D. Narasimhulu, P. John, B. Gartrell, M. Schoenberg, and X. Zang. 2017. The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. Urol Oncol

 

 

 

Lara Kleinfelter, Chandran Lab 

Kleinfelter, L. M., R. K. Jangra, L. T. Jae, A. S. Herbert, E. Mittler, K. M. Stiles, A. S. Wirchnianski, M. Kielian, T. R. Brummelkamp, J. M. Dye, and K. Chandran. 2015. Haploid genetic screen reveals a profound and direct dependence on cholesterol for hantavirus membrane fusion. mBio 6

Hastie, K. M., M. A. Zandonatti, L. M. Kleinfelter, M. L. Heinrich, M. M. Rowland, K. Chandran, L. M. Branco, J. E. Robinson, R. F. Garry, and E. O. Saphire. 2017. Structural basis for antibody-mediated neutralization of Lassa virus. Science 356: 923-928

 

 

 

Jamie Moore, Chandran Lab 

Spaulding, E., D. Fooksman, J. M. Moore, A. Saidi, C. M. Feintuch, B. Reizis, L. Chorro, J. Daily, and G. Lauvau. 2016. STING-licensed macrophages prime type I IFN production by plasmacytoid dendritic cells in the bone marrow during severe Plasmodium yoelii malaria. PLoS Pathog 12: e1005975

 

 

 

Kim Ohaegbulam, Zang Lab 

Zhao, R., J. M. Chinai, S. Buhl, L. Scandiuzzi, A. Ray, H. Jeon, K. C. Ohaegbulam, K. Ghosh, A. Zhao, M. D. Scharff, and X. Zang. 2013. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A 110:9879-9884

Abadi, Y. M., H. Jeon, K. C. Ohaegbulam, L. Scandiuzzi, K. Ghosh, K. A. Hofmeyer, J. S. Lee, A. Ray, C. Gravekamp, and X. Zang. 2013. Host B7x promotes pulmonary metastasis of breast cancer. J Immunol 190:3806-3814

Jeon, H., K. C. Ohaegbulam, Y. M. Abadi, and X. Zang. 2013. B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two cities. Oncoimmunology 2:e24744

Jeon, H., V. Vigdorovich, S. C. Garrett-Thomson, M. Janakiram, U. A. Ramagopal, Y. M. Abadi, J. S. Lee, L. Scandiuzzi, K. C. Ohaegbulam, J. M. Chinai, R. Zhao, Y. Yao, Y. Mao, J. A. Sparano, S. C. Almo, and X. Zang. 2014. Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep 9:1089-1098

Janakiram, M., J. M. Chinai, S. Fineberg, A. Fiser, C. Montagna, R. Medavarapu, E. Castano, H. Jeon, K. C. Ohaegbulam, R. Zhao, A. Zhao, S. C. Almo, J. A. Sparano, and X. Zang. 2015. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin Cancer Res 21:2359-2366

Ohaegbulam, K. C., A. Assal, E. Lazar-Molnar, Y. Yao, and X. Zang. 2015. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21:24-33

Picarda, E., K. C. Ohaegbulam, and X. Zang. 2016. Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res 22: 3425-3431

 

 

 

Anna Wec, Chandran Lab 

Howell, K. A., X. Qiu, J. M. Brannan, C. Bryan, E. Davidson, F. W. Holtsberg, A. Z. Wec, S. Shulenin, J. E. Biggins, R. Douglas, S. G. Enterlein, H. L. Turner, J. Pallesen, C. D. Murin, S. He, A. Kroeker, H. Vu, A. S. Herbert, M. L. Fusco, E. K. Nyakatura, J. R. Lai, Z. Y. Keck, S. K. Foung, E. O. Saphire, L. Zeitlin, A. B. Ward, K. Chandran, B. J. Doranz, G. P. Kobinger, J. M. Dye, and M. J. Aman. 2016. Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep 15: 1514-1526

Wec, A. Z., E. K. Nyakatura, A. S. Herbert, K. A. Howell, F. W. Holtsberg, R. R. Bakken, E. Mittler, J. R. Christin, S. Shulenin, R. K. Jangra, S. Bharrhan, A. I. Kuehne, Z. A. Bornholdt, A. I. Flyak, E. O. Saphire, J. E. Crowe, Jr., M. J. Aman, J. M. Dye, J. R. Lai, and K. Chandran. 2016. A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses. Science 354: 350-354

Froude, J. W., T. Pelat, S. Miethe, S. E. Zak, A. Z. Wec, K. Chandran, J. M. Brannan, R. R. Bakken, M. Hust, P. Thullier, and J. M. Dye. 2017. Generation and characterization of protective antibodies to Marburg virus. MAbs 9: 696-703

Wec, A. Z., A. S. Herbert, C. D. Murin, E. K. Nyakatura, D. M. Abelson, J. M. Fels, S. He, R. M. James, M. A. de La Vega, W. Zhu, R. R. Bakken, E. Goodwin, H. L. Turner, R. K. Jangra, L. Zeitlin, X. Qiu, J. R. Lai, L. M. Walker, A. B. Ward, J. M. Dye, K. Chandran, and Z. A. Bornholdt. 2017. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169: 878-890

Zhao, X., K. A. Howell, S. He, J. M. Brannan, A. Z. Wec, E. Davidson, H. L. Turner, C. I. Chiang, L. Lei, J. M. Fels, H. Vu, S. Shulenin, A. N. Turonis, A. I. Kuehne, G. Liu, M. Ta, Y. Wang, C. Sundling, Y. Xiao, J. S. Spence, B. J. Doranz, F. W. Holtsberg, A. B. Ward, K. Chandran, J. M. Dye, X. Qiu, Y. Li, and M. J. Aman. 2017. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell 169: 891-904

 

 

 

Click here to log in